Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio reported second quarter results for 2022, highlighting significant clinical advancements for ADI-001, which achieved a 75% complete response rate in patients with relapsed aggressive NHL. The FDA granted Fast Track Designation for this investigational therapy. Financially, the company holds $304.3 million in cash as of June 30, 2022, following a successful at-the-market share offering generating $45 million. Despite a net loss of $22.5 million for the quarter, the company is well-capitalized to support operations through the first half of 2025.
Adicet Bio (NASDAQ: ACET), a clinical-stage biotechnology firm focused on allogeneic gamma delta CAR T cell therapies for cancer, announces management's participation in three investor conferences in August 2022. CEO Chen Schor will engage in a fireside chat at the BTIG Biotech Conference on August 8, participate in a virtual panel at the Wedbush Pacgrow Healthcare Conference on August 10, and present a corporate overview at the Canaccord Genuity Annual Growth Conference on August 11. Live webcasts will be accessible on the company’s investor website.
Adicet Bio, a clinical-stage biotechnology company, announced the granting of inducement awards on July 29, 2022, to seven new employees as part of its 2022 Inducement Plan. These awards consist of non-qualified stock options for a total of 87,000 shares at an exercise price of $16.89 each, corresponding to the stock's closing price on the grant date. The options will vest over four years, with one-fourth vesting on the one-year anniversary of the employees' start dates. This action is a strategic move to enhance employment incentives and attract talent in line with Nasdaq rules.
Adicet Bio, a clinical-stage biotechnology firm, has announced the granting of inducement awards on June 30, 2022, to ten new employees. The awards consist of non-qualified stock options for a total of 85,200 shares, priced at $14.60 each, reflecting the stock's closing price on that date. The vesting schedule spans four years, with a quarter vesting on the one-year anniversary of each employee’s start date, and the remainder vesting in monthly installments. This initiative follows the 2022 Inducement Plan authorized by the board in January 2022.
Adicet Bio, Inc. (Nasdaq: ACET) will participate in two significant investor conferences in June 2022. The first event is the Truist Securities Cell Therapy Symposium on June 28, where CEO Chen Schor will discuss key innovations in oncology at 11:30 A.M. ET. The second event is the Stifel 2022 Virtual Cell Therapy Summit from June 29-30, featuring a panel on new cell types on June 29 at 1:00 P.M. ET. Adicet focuses on allogeneic gamma delta T cell therapies for cancer, enhancing tumor targeting and immune response.
Adicet Bio announced positive interim results for ADI-001, showing a 75% overall response rate and a 100% complete response rate in patients with relapsed/refractory Non-Hodgkin’s Lymphoma as of May 31, 2022. The Phase 1 study results indicate a favorable safety profile with no instances of dose-limiting toxicities or severe adverse events. Notably, 50% of evaluable patients with at least six months of follow-up remain cancer-free. The company aims to identify a recommended Phase 2 dose in late 2022 and plans to initiate pivotal studies in early 2023.
Adicet Bio, Inc. (Nasdaq: ACET) announced the granting of inducement awards on May 31, 2022, as part of its 2022 Inducement Plan to four employees hired in May 2022. The awards consist of non-qualified stock options for a total of 100,800 shares with an exercise price of $11.82 per share, the closing price on the grant date. The vesting schedule allows for one-fourth of the options to vest annually, with complete vesting occurring over four years, contingent on continued employment.
Adicet Bio, Inc. (ACET) announced positive preliminary results from its Phase 1 trial of ADI-001 for relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (NHL). As of February 14, 2022, the therapy showed a 67% complete response rate and a favorable safety profile, with no Grade ≥ 3 adverse events. Updated data will be presented at the ASCO Annual Meeting on June 6, 2022. Two patients maintained their complete response for over three months, despite one patient’s unrelated COVID-19 complications.
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company, announced participation in two investor conferences in May and June 2022. The H.C. Wainwright Global Investment Conference will occur from May 23-26, with an on-demand presentation available from May 24 at 7:00 A.M. ET. The Jefferies Healthcare Conference runs from June 8-10, featuring a presentation by CEO Chen Schor on June 10 at 8:30 A.M. ET. Live webcasts will be accessible via Adicet’s Investors section on their website.
Adicet Bio, Inc. (Nasdaq: ACET) announced its financial results for Q1 2022, reporting a net income of $4.6 million, compared to a net loss of $21.3 million in the same period last year. The company maintains a strong cash position with $277.9 million as of March 31, 2022. Significant operational highlights include the acceptance of interim data from the ADI-001 Phase 1 trial for oral presentation at the ASCO Annual Meeting and the granting of Fast Track Designation by the FDA for ADI-001 targeting Non-Hodgkin’s lymphoma. R&D expenses rose to $13.5 million.